Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based CEO’ operating in the Health Care space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Rachel E. Haurwitz
Co-founder, President & CEO of Caribou Biosciences
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
Follow Rachel E. Haurwitz:
About Caribou Biosciences: Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Noubar Afeyan
Founder & CEO of Flagship Pioneering
Noubar Afeyan is Founder, Senior Managing Partner and Chief Executive Officer at Flagship Ventures, a leading early stage venture capital firm. Noubar also leads the firm’s VentureLabs unit that invents and launches transformative startups. Noubar is a Senior Lecturer at MIT’s Sloan School of Management where he has taught courses on technology-entrepreneurship, innovation and leadership since 2000. Noubar lectures widely in the United States and internationally on diverse topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy. During his 28-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build over 35 successful life science and technology startups. Noubar was Founder and Chief Executive Officer at PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive’s acquisition by Perkin Elmer/Applera Corporation in 1998, Noubar was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including CiBO Technologies, Epiva BioSciences, Evelo BioSciences, Joule Unlimited, Kaleido BioSciences, Moderna Therapeutics, Pronutria Biosciences and Seres Therapeutics. Previously, Noubar was a Member of the founding team, Director and Investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), Adnexus Therapeutics (acquired by Bristol-Myers Squibb) and Affinnova (acquired by AC Nielsen). Noubar received a Technology Pioneer 2012 award from the World Economic Forum in recognition of the breakthrough solar fuel technology being developed at Joule Unlimited. Noubar has served as Chairman of the Global Agenda Council on Chemicals, Advanced Materials and Biotechnology of the World Economic Forum as well as being a member of the Meta-Council on Emerging Technologies. Noubar is a Member of the Board of Overseers of the Boston Symphony Orchestra. In addition, he serves on the board of AmeriaBank and of UWC Dilijan International School, both of Armenia. Previously, Noubar was a Co-Founder and Member of the Board of Directors at National Competitiveness Foundation of Armenia, a private-public partnership dedicated to promoting economic development in the former Soviet Republic of Armenia. In 2008 Noubar received the Ellis Island Medal of Honor, an award granted to outstanding Americans who have distinguished themselves as United States citizens and who have enabled their ancestry groups to maintain their identities while becoming integral parts of American life. Noubar has authored numerous scientific publications and patents since earning his Ph.D. in Biochemical Engineering from MIT in 1987. Cygnal is a best-in-class team of biomedical experts and leaders collaborating to revolutionize how the world treats diseases.
Follow Noubar Afeyan:
About BIND Therapeutics, Cogen Therapeutics, Cygnal Therapeutics, Ensemble Therapeutics, Flagship Pioneering, Generate Biomedicines, Harvard Business School, Indigo, Joule Unlimited Technologies, Laronde, Massachusetts Institute of Technology, Moderna Therapeutics, Omega Therapeutics, Permeon Biologics, Ring Therapeutics, Rubius Therapeutics, Seres Therapeutics: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Simba Gill
President & CEO of Evelo Biosciences
Simba Gill, PhD is an entrepreneur, investor and CEO who believes passionately that science and globalization will dramatically improve life in the 21st century. Dr. Gill is currently the CEO of Evelo, Sr. Partner at Flagship Ventures, and Executive Chair of Blackfynn. Dr. Gill founded or had lead roles in moksha8, Epirus, Maxygen, Verdia, Avidia, Codexis, Systemix and Valentis, four of these companies have been taken public and three were acquired through strategic trade sales. Exit valuations were between $400M – $6B. Dr. Gill has also led, built and launched several commercial businesses/products generating annual revenues of between $150M-$2B. Dr. Gill has founded and/or had lead roles in pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, immunodiagnostics and the cancer microbiome. He has also been an investor, advisor, founder and CEO of several emerging market life science companies. Dr. Gill was a Partner at TPG, focused on investments in Life Sciences and Emerging Markets. Early in his career, Dr. Gill was co-head of Worldwide Marketing for Recormon. He also led corporate and market development and strategy from inception to commercialization of the Elecsys system, which became one of the world’s most widely used immunodiagnostic platforms. Dr. Gill served on the Board of Directors of the Tuberculosis Alliance, The Djerassi Resident Artists Program and the International Advisory Board of INSEAD. Dr. Gill was also the founder of Dispatches, an in-depth written and photojournalism periodical focused on key global issues. Dr. Gill has an MBA from INSEAD and carried out his PhD with focus on developing humanized antibodies to treat cancer. This work was done at King’s College, London in collaboration with the LMB at Cambridge and Celltech.
Follow Simba Gill:
About Epiva, Evelo Biosciences, moksha8 Pharmaceuticals, TPG Growth: Evelo Biosciences is dedicated to improving the lives of patients globally through the development of monoclonal microbials.
Boris Lipchin
Founder and CEO of BRIO Systems
Boris Lipchin, co-founder and CEO of Brio Systems, Inc.. Boris was previously a co-founder and CTO of Airmada, Inc. before Airmada four years as a flight software engineer, launch operator and GN&C engineer for SpaceX.
Follow Boris Lipchin:
About Brio, BRIO Systems, Techstars: BRIO Systems offers a complete COVID-19 testing system to help employers keep teams safe and businesses on track.
Andrew Beck
Co-founder & CEO of PathAI
Andrew Beck earned a Bachelors of Arts in History from Brown University in 2002 and completed a Masters of Medical Science in Biostatistics and a Medical Degree from Brown Medical School in 2006. He completed his residency in Anatomic Pathology and clinical fellowship in Molecular Genetic Pathology from Stanford in 2010.He then joined the Advanced Residency Training at Stanford program and completed a PhD in Biomedical Informatics from Stanford University in 2013, working with Professor Daphne Koller. In 2011, he was appointed as an Assistant Professor in the Departmet of Pathology at Harvard Medical School and the Beth Israel Deaconess Medical Center. In 2016, he was promoted to Associate Professor. In 2016, Dr Beck co-founded PathAI, a company that develops artificial intelligence technology for pathology, where he serves as President and CEO.
Follow Andrew Beck:
About Beth Israel Deaconess Medical Center, PathAI: PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time.
Aoife Brennan
CEO of Synlogic
Aoife Brennan joined Synlogic in September 2016 as chief medical officer and is responsible for the oversight and direction of the company’s clinical development strategy and operations. Aoife previously spent six years at Biogen, where she was in roles of increasing responsibility and most recently served as vice president and head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial. She has also led programs across multiple therapeutic areas including the late phase development of nusinersen for spinal muscular atrophy and ALPROLIX™ and ELOCTATE™, treatments for Hemophilia B and Hemophilia A. Prior to joining Biogen, she was director of clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes. Aoife holds a medical degree from Trinity College in Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.
Follow Aoife Brennan:
About Synlogic: Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Khaled Kteily
Founder & CEO of Legacy
Khaled Kteily is the Founder & CEO of Legacy, a digital fertility clinic for men helping change the outdated view that fertility is a “women’s issue”. Legacy is a graduate of Harvard’s Innovation Labs and Y Combinator, has raised over $20M from top-tier investors like FirstMark Capital & Bain Capital Ventures, as well as celebrities like Justin Bieber and DJ Khaled. The company works with leading insurers, military partners, and clinics in additions to its Direct to Consumer offering. A former healthcare consultant at Oliver Wyman in Toronto, Khaled studied public policy at the Harvard Kennedy School, where he received a full scholarship and graduated with distinction. He previously graduated with a triple concentration from McGill University in Montreal, Canada. Khaled is a member of the Young Presidents Organization (YPO), is an Aspen Ideas Health Scholar, and a World Economic Forum Global Leadership Fellow. He was recently recognized as 40 under 40 by the Arab America Foundation. He serves on the boards of the Harvard Kennedy School’s Center for Public Leadership (Alumni Council) and the Harvard Arab Alumni Association.
Follow Khaled Kteily:
About Legacy: Legacy is a digital fertility clinic for men, founded at Harvard & backed by Y Combinator, FirstMark Capital, Bain Capital and celebrities.
Prady Tewarie
CEO of AZOTH LLC
Tewarie Enterprises, PRT Holding Group, AZOTH LLC, Ohner
Follow Prady Tewarie:
About AZOTH LLC, Human Performance Science, The Tewarie Group LLC.: Nootropic Vitamins/Supplements
Alicia Chong Rodriguez
Co-Founder and CEO of Bloomer Health Tech
Alicia Chong Rodriguez is the founder and CEO of Bloomer Tech. She holds two master’s degrees in engineering and management/integrated design and electrical engineering and computer science (EECS) from Massachusetts Institute of Technology (MIT).
Follow Alicia Chong Rodriguez:
About Bloomer Health Tech: Bloomer Tech uses everyday fabrics and machine learning for personalized detection, monitoring, and treatment of chronic diseases.
Michel Vounatsos
Chief Executive Officer of Biogen Idec
Michel Vounatsos is Executive Vice President and Chief Commercial Officer at Biogen. Michel brings extensive global biopharmaceutical experience and a track record of innovative stakeholder engagement to his leadership of the company’s commercial organization. Michel joined Biogen in 2016 after a 20 career at Merck, where he most recently served as President, Primary Care Business Line and Merck Customer Centricity. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups, and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payers and retailers and the world’s largest governments. Michel previously held leadership positions across Europe and in China for Merck. Earlier in his career, Michel held management positions at Ciba-Geigy. Michel received his C.S.C.T. certificate in Medicine from the Universite Victor Segalen, Bordeaux II, France, and his M.B.A. from the HEC School of Management in Paris.
Follow Michel Vounatsos:
About Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Bicheng Han
CEO of BrainCo
Bicheng Han is the founder and CEO of Brainco. He founded the company in 2014. A year after, Han founded BrainRobotics. Han earned his PhD from Harvard University, Center of Brain Science. He is a brain science, medical device expert.
Follow Bicheng Han:
About BrainCo, BrainRobotics, Harvard University: BrainCo strives to apply brain machine interface (BMI) and neurofeedback training to optimize the potential of the human brain.
Tom Simmons
Founder & CEO of Supplant
Tom has over 10 years of experience in carbohydrate biochemistry. He formerly held fellowships at the University of Cambridge and at the World Economic Forum and has advocated sugar reduction initiatives through Sky News and Channel 4 television appearances.
Follow Tom Simmons:
About Cambridge Judge Business School, Supplant: Supplant is a biotechnology platform that makes sugar substitutes.
Shinta Nurfauzia
Co-Founder & CEO of Lemonilo
Shinta Nurfauzia is Co-Founder & CEO at Konsula.
Follow Shinta Nurfauzia:
About Lemonilo: Lemonilo is a curated marketplace for healthy food and cosmetics.
Tony Coles
Chairman and CEO of Yumanity Therapeutics
Anthony Coles was named Chairman and Chief Executive Officer of Yumanity Therapeutics, LLC, a company focused on transforming drug discovery for neurodegenerative diseases, in October 2014. Prior to this, from October 2013, Anthony Coles served as Chairman and CEO of TRATE Enterprises LLC, a privately-held company. Anthony Coles served as President, Chief Executive Officer and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company (“Onyx”), from 2012 until 2013, having served as its President, Chief Executive Officer and a member of its board of directors from 2008 until 2012. Prior to joining Onyx in 2008, he was President, Chief Executive Officer and a member of the board of directors of NPS Pharmaceuticals, Inc., a public biopharmaceutical company (“NPS”). Before joining NPS in 2005, he served in various leadership positions in the biopharmaceutical and pharmaceutical industries, including at Merck & Co., Inc., Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated. In addition to having previously served as a director of Onyx and NPS, he was formerly a director of Laboratory Corporation of America Holdings and Campus Crest Communities, Inc. Anthony Coles has been a director of the Company since April 2014. He is a member of the Compensation Committee and the Finance Committee.
Follow Tony Coles:
About Yumanity Therapeutics: Yumanity Therapeutics is a biotechnology company that transforms drug discovery for diseases caused by protein misfolding.
Emil Hewage
Co-Founder & CEO of BIOS
Emil’s academic background is as a PhD researcher in computational neuroscience and machine learning. He brings knowledge of neural signalling and signal processing with over 7 year’s industrial & academic R&D experience. He has previously developed medical devices with Siemens Healthcare and Sphere Medical as well as having held roles in finance and medical and cleantech startups.
Follow Emil Hewage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Mark Kotter
Founder/CEO of bit.bio
Mark Kotter is the founder and CEO of bit.bio.
Follow Mark Kotter:
About bit.bio: Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell.
Matteo Lai
Co-founder & CEO of Empatica
Matteo Lai is co-founder and CEO of Empatica, a human data analytics company based in Milan and Boston. Empatica sells the world’s smallest and most accurate wearable sensor for research, and it recently launched Embrace, the first medical grade wearable designed to save lives for people with Epilepsy and Autism. He holds a Master in Innovation Management from Alta Scuola Politecnica. He also studied engineering, trained as an architect, and holds a Double MSc degree in Architecture from Milan’s Polytechnic and Turin’s Polytechnic.
Follow Matteo Lai:
About Empatica: Empatica is an affective computing company focused on human data analytics.
Laura D’Asaro
Co-Founder & CEO of Chirps Chips (Six Foods)
Follow Laura D’Asaro:
About Chirps Chips (Six Foods): Chirps Chips is a creating edible insect foods for healthyeating and sustainability.
Philipp Schulte
CEO of Baze
Philipp brings more than 10 years of experience in life sciences with a focus on innovation, marketing, and strategy. He is currently facing his most uphill struggle yet: getting his young daughter to have her full plate of nutrients. When he’s not at home or the office and it is cold enough he can be found trying to achieve his life goal of getting more than 100 ski days in a year.
Follow Philipp Schulte:
About Baze: Baze are enable every person to achieve their best health through a science-led, results-driven food and supplement platform.
Hugh O’Dowd
President & CEO of Neon Therapeutics
Neon Therapeutics’ chief executive officer, Hugh O’Dowd, joined the company in 2016, bringing more than 20 years of expertise in pharmaceutical leadership and moving important oncology therapies from clinical development through commercialization. Hugh joined Neon Therapeutics from Novartis Oncology, where he spent more than 20 years in a variety of leadership roles, including chief commercial officer and head of global strategy. In this role, he was responsible for global commercialization for the oncology portfolio, including global brand leadership, health economics and pricing, early phase commercial development, strategic capabilities, business development, and licensing and global sales excellence. Hugh began his career in pharmaceuticals in 1992 at Glaxo in sales, and moved to Novartis in 1996. Following a career of increasing levels of responsibility in sales and marketing, he took a leading role in the commercialization of Gleevec, and assumed country- and region-level commercial leadership roles before overseeing the entirety of Novartis Oncology commercialization and strategy in 2011. Since 2015, Hugh was country president and general manager of Novartis in the United Kingdom and Ireland. Hugh holds a B.A. from Loyola University Chicago, and an MBA from the Kellstadt Graduate School of Business at DePaul University Chicago.
Follow Hugh O’Dowd:
About Neon Therapeutics: NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Nan-Wei Gong
Co-founder & CEO of FIGUR8
Dr. Nan-Wei Gong is a researcher, engineer and serial entrepreneur. She is the co-founder and CEO of figur8 Inc, and a research affiliate of the MIT Media Lab. Her first start-up, 3dim Tech Inc, received the grand prize of the MIT $100K entrepreneurship competition in 2013, selected in the Global Founders’ Skill Accelerator and was acquired in 2014. She founded Circular2 in 2014 – a technical consulting agency that specialized in on body sensing, low-power wearable electronics and digital textile research and development. Their clients include top universities – MIT, Harvard – and fortune 500 companies such as Google and Samsung. Her past work includes flexible and customizable printed sensing surfaces for gestural control, time-of-flight modules for 3D gesture tracking, and wearable sensing for dynamic management of ubiquitous media. She publishes her research extensively at top-tier computer science conferences and journals including best papers at CHI, UbiComp, UIST and IEEE pervasive magazine. She has worked in a number of industrial research labs, among them Microsoft Research and the Nokia Research Center, and was assigned as the R&D lead of Project Jacquard at Google ATAP in 2014-2016. She holds a PhD and MS degree in Media Arts and Sciences from the MIT Media Lab and a MS in Materials Science and Engineering from National Tsing Hua University in Taiwan.
Follow Nan-Wei Gong:
About FIGUR8, MIT Media Lab: FIGUR8 is the most advanced on-body movement intelligence solution for evaluating musculoskeletal health.
Quintus Liu
Chairman & CEO of Healthera
Quintus is a professional healthcare entrepreneur and investor who ideated the concept of patient-centric digital care known as Healthera.
Follow Quintus Liu:
About Healthera: Transforming the way a nation delivers its healthcare to its population, from prescriptions to personalised services.
Romesh Subramanian
CEO and Founder of Dyne Therapeutics
Romesh Subramanian is the CEO and founder of Dyne Therapeutics.
Follow Romesh Subramanian:
About Dyne Therapeutics: Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.
Jonathan Ng
Founder and CEO of Iterative Scopes
Jonathan Ng is the founder and CEO of Iterative Scopes.
Follow Jonathan Ng:
About Iterative Scopes: Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space.
Jacob Rothman
CEO and Co-Founder of Perch
Co-Founder and CEO of Perch. Trying to revolutionize fitness technology. Learning something new everyday. MIT Grad.
Follow Jacob Rothman:
About Perch: Perch utilizes cameras mounted to weight racks to measure, store, and analyze weightlifting performance.
John Leonard
President , Chief Executive Officer & Member Board of Directors of Intellia Therapeutics
After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality. John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research. In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of QuintilesIMS (NYSE:Q) and Chimerix (Nasdaq:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.
Follow John Leonard:
About Intellia Therapeutics: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Paulina Chilarska
CEO & Founder of Cambridge Biolabs
Chilarska’s cutting-edge work at the University of Cambridge was funded by the prestigious 4-Year Wellcome Trust PhD award in Stem Cell Biology. Already at the age of 21 she worked with the Nobel Prize winner Sir Professor Paul Nurse on the cell cycle thus investigating the mechanisms underlying carcinogenesis. Dr Chilarska is an expert in the molecular basis of ageing and strongly believes that ageing is a disease which can be prevented and treated. She is currently wirting a book describing her revolutionary approach to Ageing Prevention and Ageing Reversal. She is fluent in five languages and has international consulting experience.
Follow Paulina Chilarska:
About Cambridge Biolabs: Biotech-meets-tech startup developing personalised skincare solutions
Paulo Garcia
CEO & Co-Founder of Kytopen
Dr. Paulo A. Garcia co-invented the Flowfect™ technology while he was a Research Scientist at MIT. He is currently leading the development and commercialization efforts of the proprietary cell engineering platform for therapeutic and biotechnology applications.
Follow Paulo Garcia:
About Kytopen: Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Nick Morrell
CEO and co-Founder of Morphogen-IX
Nick is the British Heart Foundation Professor of Cardiopulmonary Medicine at the University of Cambridge, based in the Department of Medicine. He has 25 years of experience working in the field of pulmonary arterial hypertension (PAH), and is the Research Director of the National Pulmonary Hypertension Service at Papworth Hospital. His research spans clinical translational studies, experimental medicine, genetics, cell and molecular biology and preclinical models of disease. He has published over 200 papers in this field and is an internationally recognised authority on the pathobiology of PAH.
Follow Nick Morrell:
About Morphogen-IX, Papworth Hospital, University of Cambridge: MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins
Ned Sahin
Co-Founder & CEO of Brain Power
Follow Ned Sahin:
About Brain Power, Harvard University, Startup Leadership Program: Brain Power builds software and hardware to transform Google Glass™ into an assistive device for people with autism.
Eric Kelsic
Founder & CEO of Dyno Therapeutics
Eric Kelsic is the Founder and CEO of Dyno Therapeutics. He is a graduate of Harvard University.
Follow Eric Kelsic:
About Dyno Therapeutics: Dyno Therapeutics is a biotechnology company that uses artificial intelligence for gene therapy.
Colin Hill
Chairman and CEO of GNS Healthcare
Colin Hill co-founded GNS Healthcare in 2000 and has served as Chairman & CEO since then. He brings impressive leadership experience and a solid track record in commercializing machine learning technology and precision medicine platforms in the biopharmaceutical and managed care industries. In 2016, he was appointed to the board of directors of a leading publically traded mobile health company that pioneered remote cardiac monitoring – Biotelemetry Inc. (formerly CardioNet) (NASDAQ: BEAT). He was appointed in 2015 by Massachusetts Governor Charlie Baker to the board of directors of the Center for Health Information and Analysis. He is also a founding board member of Transforming Medicine: The Elizabeth Kauffman Institute, a non-profit foundation (501c3) dedicated to the advancement of personalized medicine. He was a founding member of the Board of Directors of AesRx, a biopharmaceutical company dedicated to the development of new treatments for sickle cell disease (acquired by Baxter in 2014). Colin was the founding chairman of O’Reilly Media’s Strata Rx in 2012, the first healthcare big data conference in the industry. Colin was the founding chairman of big data quantitative trading firm Fina Technologies and served from 2008 to 2011. In 2004, Colin was named to MIT Technology Review’s TR100 list of the top 100 innovators in the world under the age of 35. He is a frequent speaker at national and international scientific and industry conferences including America’s Health Insurance Plans (AHIP) annual meeting, the Pharmaceutical Researchers & Manufacturers of America (PhRMA) annual meeting, and the Forbes Healthcare Summit, and has been quoted in and appeared in numerous publications and television programs, including The Wall Street Journal, CNBC Morning Call & SquawkBox, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist. He graduated from Virginia Tech with a degree in physics and earned Master’s degrees in physics from both McGill University and Cornell University.
Follow Colin Hill:
About GNS Healthcare: GNS Healthcare is a big data analytics company focuses on discovering what works in the healthcare industry and for whom.
Benedikt von Thungen
CEO of Sanome
I’m the CEO and Co-Founder of Sanome, thanks for stopping by. My academic background is in biosciences. Along with experience in building software companies, I am so excited about the interface of the two fields and how they will change the healthcare industry. I started my entrepreneurial journey during my undergraduate degree and have since built multiple companies across renewable energy, enterprise software, AI, drug discovery, and healthcare. I love building and scaling winning teams in exceptional companies. My long-term vision is to build a human digital twin (a virtual representation of everyone’s biology & health) that allows us to predict any changes to someone’s health before they actually occur, thus enabling true preventative healthcare.
Follow Benedikt von Thungen:
About Sanome: Transforming diagnostics for all
Frank Reynolds
Chairman of the Board, CEO, CFO, CSO & Co-Founder of PixarBio
Follow Frank Reynolds:
About PixarBio: PixarBio Corp is a specialty Biotechnology company focused on pre-clinical and commercial development of new products.
Madhavi Gavini
CEO and Founder of Droplette
Follow Madhavi Gavini:
About Droplette: Droplette is a needle-free and hand-held device that delivers large molecules deep through skin.
Diego Miralles
CEO of Vividion Therapeutics
Diego Miralles is the Chief Executive Officer at Vividion Therapeutics.
Follow Diego Miralles:
About Flagship Pioneering, Laronde, Vividion Therapeutics: Vividion is a developer of a novel drug discovery platform designed to offer transformative treatments to patients with serious illnesses.
Phillip Ragon
Founder & CEO of Intersystems
Since founding InterSystems in 1978, Ragon has led the company to worldwide prominence in the database, interoperability, and healthcare application markets. Prior to starting InterSystems, Ragon co-founded a healthcare software company that became a leader in the U.S. and is now part of GE Healthcare. He has served as a healthcare IT consultant to academic and government institutions and received a prestigious Ernst & Young Entrepreneur of the Year award in healthcare information technology. Ragon is a Trustee of the Massachusetts General Hospital (MGH), where he also served as Honorary Co-Chair of the MGH Campaign. He is on the Harvard Medical School Board of Fellows. He is also a member of the MIT Corporation, the governing body of MIT, and chairs the Visiting Committee that reviews the Physics Department. In 2008, Ragon helped created the Ragon Institute, a joint research center of MGH, MIT, and Harvard. The vision of the Ragon Institute is to harness the immune system through science to prevent and cure disease, and its immediate objective is the creation of a vaccine for HIV. The son of a U.S. Air Force fighter pilot, Ragon was born in Arizona. He grew up in a variety of states and graduated from high school in Bogota, Colombia. He obtained an S.B. (B.S) in physics from MIT.
Follow Phillip Ragon:
About Intersystems: InterSystems is a vendor of software and technology for high-performance database management, integration, and health information systems.
Tim Guilliams
Founder, CEO of Healx
Tim is a social entrepreneur passionate about delivering the next generation of therapeutics to rare disease patients in need. He is the Founder and Chief Executive of Healx and the Co-Founder and Chair of the Cambridge Rare Disease Network (CRDN), a charity aiming to foster dialogue and awareness around rare diseases in Cambridge, UK. Prior to Healx and CRDN, Tim worked on University-Industry interactions and cluster dynamics in the area of Life Sciences for the UK Government Department for Business, Innovation and Skills (BIS). He obtained his PhD in the field of Biophysical Neuroscience at the University of Cambridge, where his research related to the development of antibody fragments as novel biophysical and therapeutic tools for Parkinson’s disease. As a PhD student, Tim co-founded multiple successful student societies, including the Cambridge University Science and Policy Exchange (CUSPE), and was involved with Innovation Forum, Oxbridge Biotech Roundtable (OBR) and the Cambridge University Technology and Enterprise Club (CUTEC). He is also a Junior Associate Fellow of the Centre for Science and Policy (CSaP). Before moving to Cambridge, he obtained an MEng & BEng in Bio-Engineering from the University of Brussels (VUB).
Follow Tim Guilliams:
About Healx: Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Steven L. Hoerter
President and CEO of Deciphera Pharmaceuticals
Steven L. Hoerter has served as our Senior Vice President, Commercial since August 2011. From 2010 to 2011, Steven Hoerter was General Manager and Management Center Head at F. Hoffmann-La Roche Ltd. for the Sub-Saharan Africa and Indian Ocean Region, based in Johannesburg, South Africa. From 2005 to 2010, Steven Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s BioOncology business as Senior Director, Pipeline Development and Commercial Operations. Prior to that he worked at Chiron Corporation and Eli Lilly and Company. During Steven Hoerter’s 11-year career at Lilly, he held positions in sales, business development, marketing and business unit management in the US, Europe and Africa. Steven Hoerter has a B.A. in Russian and Political Science from Bucknell University, an M.B.A. from Tilburg University and a M.S. in Management from Purdue University.
Follow Steven L. Hoerter:
About Deciphera Pharmaceuticals: Deciphera Pharmaceuticals focuses on improving kinase inhibitor treatments.
Chris Torrance
Co-Founder and CEO of PhoreMost
Chris has significant oncology research and development experience, including six years as a senior manager at Cambridge-based pharmaceutical company, Vernalis. His principle expertise lies in cancer cell biology and drug discovery. In this field, he has led project teams taking drug targets from inception through to hit identification, lead optimisation and into preclinical studies. Chris holds a PhD from East Carolina University and completed a Post-Doctoral position in the world renowned oncology laboratory of Professor Bert Vogelstein (Johns Hopkins University) where he pioneered the use of X-MAN™ cancer models in high-throughput screening and drug discovery.
Follow Chris Torrance:
About PhoreMost: PhoreMost is a new-model drug discovery company based in Cambridge, UK.
Trey Foskett
Co-Founder and CEO of Watchmaker Genomics
Trey Foskett is the Co-Founder and CEO of Watchmaker Genomics.
Follow Trey Foskett:
About Watchmaker Genomics: Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA.
Thomas Weaver
Founder & CEO of PetMedix
Tom holds a PhD in Experimental Oncology and has served in a variety of research, technology development and commercial roles. He has a proven track record of creating value in highly successful start-up companies applying genome-based technologies and contract services for fundamental research, clinical, and drug discovery purposes. He has also led large infrastructure programs in genomics and animal model genetics, serving as a Director at the Medical Research Council (Oxford, UK). He trained at the University of Cambridge and MRC Lab for Molecular Biology (Cambridge, UK), and the University of Wisconsin Medical School, (Madison, USA).
Follow Thomas Weaver:
About PetMedix: PetMedix is a pet therapeutics startup.
Jacob Drucker
Co-founder and CEO of Supply Clinic
Follow Jacob Drucker:
About Supply Clinic: How smart dentists shop for supplies
Bo Cumbo
President & Chief Executive Officer of AavantiBio
Alexander Bo Cumbo, based in Greater Boston Area, is the Executive Vice President and Chief Commercial Officer at Sarepta Therapeutics. He has a BS in Laboratory Technology from Auburn University. Formerly, Bo was on the Board of Ra Pharmaceuticals. Prior to his work with Sarepta, Bo served at Ra Pharmaceuticals. For more on Alexander Bo Cumbo, be sure to follow him online for the latest insights and updates.
Follow Bo Cumbo:
About AavantiBio: AavantiBio is a biopharmaceutical company that provides gene transfer and gene editing therapies to treat genetic diseases.
David R. Elmaleh
Scientific Founder, CEO and Chairman of AZTherapies
David R. Elmaleh is the founder of [Mersana Therapeutics](https://www.crunchbase.com/organization/mersana-therapeutics#/entity). Previously, he served as the chairman and president of AZTherapies. Elmaleh obtained a bachelor’s degree in chemistry and physics, and master’s degree and PhD in organic chemistry from Hebrew University.
Follow David R. Elmaleh:
About AZTherapies, Mersana Therapeutics: AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Glenn Larsen
Co-Founder, President & CEO of Aquinnah Pharmaceuticals
Glenn Larsen is a Co-Founder, President & Chief Executive Officer at Aquinnah Pharmaceuticals since 2014. Aquinnah is a pharmaceutical company focused on the development of new therapies for ALS and neurodegenerative diseases. Glenn brings significant experience from his tenure in the discovery, development and commercialization of pharmaceutical, biotech and regenerative medicines, including raising approximately $65 million in private venture funding. Glenn has been closely involved with the commercial registration of five biologics and led teams that advanced over 15 new biologic and small molecule chemical entities to clinical development. Previously, Glenn was the Vice President of Musculoskeletal Sciences at Wyeth (Pfizer); directing R&D in the fields of arthritis, pain, inflammation and tissue regeneration, including responsibility for the global development and commercial efforts of Enbrel, an anti-TNF therapeutic. Glenn also served as Vice President of Preclinical Research and Development at Genetics Institute, responsible for all preclinical activities needed to identify and advance drug candidates to clinical trials for evaluation in the fields of oncology, inflammation, immunology, hemophilia, hematopoiesis and tissue regeneration programs. Glenn currently serves on the Board of Directors of Aquinnah Pharmaceuticals, Anika Therapeutics, 180 Therapeutics and previously Hydra Biosciences; and has held prior senior executive leadership roles at Hydra Biosciences and SpringLeaf Therapeutics. Glenn received his Ph.D. in Biochemistry from Stony Brook University and is a PMD Graduate of Harvard Business School.
Follow Glenn Larsen:
About Aquinnah Pharmaceuticals: Aquinnah Pharmaceuticals is a National Institute of Neurological Disorders and Stroke
Donald Nicholson
CEO of Nimbus Therapeutics
Follow Donald Nicholson:
About Nimbus Therapeutics: Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company.
Jason Mellad
CEO of Start Codon
Follow Jason Mellad:
About Start Codon: Translating disruptive research into successful start-ups, the Cambridge way
Caroline Loew
President & Chief Executive Officer of Glympse Bio
Caroline Loew is the President and Chief Executive Officer at Glympse Bio.
Follow Caroline Loew:
About Glympse Bio: Glympse Bio is a biotechnology company that transforms disease detection and predict treatment response.
Todd Krueger
President & CEO of AOBiome
Todd Krueger is the Chief Executive Officer, President and a Director of our Company. He is primarily responsible for the overall management, corporate development and strategic planning of our Company and has been with the company since 2015. Mr. Krueger graduated from Northwestern University, United States, with a Bachelor of Economics degree with Highest Distinction, and earned his Master of Business Administration degree from the Kellogg School of Management, Northwestern University, United States. Prior to joining us, Mr. Krueger had over 20 years of experience in healthcare strategy, business development, operations and finance. He started his career as a consultant for Bain and Company, a management consulting firm, from 1990 to 1993, responsible for providing strategic analysis and solution implementation to Fortune 500 clients. In 1999, Mr. Krueger co-founded Fluidigm Corporation, which is principally engaged in the design, manufacture and sale of biological research equipment and is currently listed on NASDAQ (stock symbol FLDM), where he served as its chief financial officer and the vice-president of business development from 1999 to 2002, responsible for strategy development, finance, business development, and operations. From 2006 to 2013 he held various senior business development and strategy roles at Applied Biosystems Inc. and later Life Technologies Corporation (which was formed as a result of the merger between Applied Biosystems Inc. and Invitrogen Corporation in 2008)), where his last role was head of business development for molecular medicine. From 2013 to 2014, he was Chief Financial Officer of Claritas Genomics, Inc., a genetic diagnostics laboratory based in the United States, and from 2014 to 2015, he was the director of strategy and operations for the Broad Institute, a biomedical and genomic research center based in the United States. He was responsible for overseeing the commercialization of the genetics platform. Mr. Krueger also currently serves as a director of General Automation Laboratory Technologies, Inc. (GALT), a microbiome tools company based in the United States.
Follow Todd Krueger:
About AOBiome: AOBiome is a life sciences company that focuses on transforming human health.
Maya R. Said
CEO and Co-Founder of Outcomes4Me
Maya Said is the Founder and CEO of Outcomes4Me.
Follow Maya R. Said:
About Outcomes4Me: Outcomes4Me is a developer of a free mobile app and platform to navigate cancer treatment and care.
Briggs Morrison
CEO of Syndax Pharmaceuticals
Briggs W. Morrison, M.D., joined MPM in 2015. Briggs is CEO of Syndax Pharmaceuticals, Inc., an MPM portfolio company. Prior to joining Syndax and MPM, Briggs served as Chief Medical Officer and Executive VP for “Global Medicines Development” at AstraZeneca (ADR). Briggs’ career includes distinguished roles at AstraZeneca, Pfizer (PFE) and Merck (MRK). At AstraZeneca, he was head of global medicines development, where he oversaw all clinical development functions and late- stage clinical development projects. As Head of Clinical Development at Pfizer, he oversaw Phase I-III development and operations for all therapeutic areas before being appointed the head of Development, Medical Affairs, Safety and Regulatory Affairs for all Pfizer human health businesses. While serving as head of Oncology Development at Merck, Briggs oversaw the development and approval of vorinostat (Zolinza ®) for the treatment of cutaneous T-cell lymphoma. Briggs formerly served as Chairman of the Board of Transcelerate, an industry-funded company charged with improving aspects of clinical trials. Briggs received his BS (Biology) degree from Georgetown University and his MD degree from the University of Connecticut, and completed a post-doctoral research fellowship in the Department of Genetics at Harvard Medical School and additional post-doctoral work at the Dana-Farber Cancer Institute. Briggs trained in Internal Medicine at the Massachusetts General Hospital and in Medical Oncology at the Dana-Farber Cancer Institute.
Follow Briggs Morrison:
About MPM Capital, Syndax Pharmaceuticals: Syndax Pharmaceuticals focuses on developing an HDAC inhibitor for solid tumors and hematological tumors.
Michael Schrader
Co-Founder & CEO of Vaxess Technologies
Michael Schrader is the CEO and co-founder of Vaxess Technologies, a company revolutionizing global health by creating heat-stable vaccines. Vaxess strives to not only lower the cost of vaccine distribution, but also increase access to life-saving products for people around the world. The company was the winner of the 2013 MassTLC Innovative Life Science Technology of the Year, 2012 Harvard Business Plan Competition and The 2012 Harvard President’s Challenge for Social Entrepreneurship. Prior to founding Vaxess, Michael worked at Google, Toyota, and Honda where he has earned fifteen patents. He holds a BSME from Purdue University and an MBA from Harvard Business School.
Follow Michael Schrader:
About Harvard University, MassChallenge, Vaxess Technologies: Vaxess Technologies engages in developing biomedical innovations with a focus on improving access to vaccines.
Boris Mordkovich
Co-Founder & CEO of EVELO Electric Bicycles
Boris Mordkovich is the co-founder of EVELO Electric Bicycle company. As a serial entrepreneur specializing in technology and alternative transportation, his goal is to get more people on bikes more often.
Follow Boris Mordkovich:
About EVELO Electric Bicycles: Smart Electric Bicycles Delivered to Your Door.
Jason Hill
Co-Founder & CEO of BeTH
Jason Hill is Founder and CEO of BeTH, a medtech start-up and pioneer of human-device interface technology aimed at delivering unprecedented healthcare savings and comfort for patients worldwide. Specific expertise in the development products that rely on novel technologies and are differentiated by human centered design. Previously principal of Sonhill Research and Design with specialty in market research, product positioning design strategy and execution for of novel technologies for various start-ups and think tank Applied Minds. Jason co-authored research framework and served as a mentor at the D-Lab at Massachusetts Institute of Technology and has lectured on design at Harvard University. Jason received a Bachelor of Science with Honors from Art Center College of Design (Pasadena) and certificate form highly selective graduate business school exchange program at INSEAD (Singapore).
Follow Jason Hill:
About BeTH: Human-device interface solutions.
Simon Read
Founder and CEO of Curie Therapeutics
Simon Read is the Founder and CEO Curie Therapeutics.
Follow Simon Read:
About Curie Therapeutics: Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Eric Mayes
CEO of Endomag
Dr Mayes has over 20 years’ experience in developing and leading materials technology companies. Prior to joining Endomag as CEO in 2010, Eric held executive positions in Cambridge Display Technology (CDT) and NanoMagnetics. He was named the Royal Society of Chemistry’s ‘Entrepreneur of the Year 2003’ for his founding role in NanoMagnetics. Eric is an advisor to the University of Texas at Austin’s ‘Texas Health Catalyst’ and the European Healthtech Translation Advisory Board (HealthtechTAB). A US-UK dual national, he holds a BSc in Physics from Arkansas State University and a PhD in Chemistry from the University of Bath. Eric is a Fellow of the Royal Society of Chemistry.
Follow Eric Mayes:
About Endomag: Endomag is a medical technology company devoted to improving breast cancer care through its magnetic sensing technologies.
Daniel Carballo
CEO & Co-Founder of Encora Therapeutics
Daniel Carballo is the CEO at Encora Therapeutics.
Follow Daniel Carballo:
About Encora Therapeutics: Encora helps people with neurodegenerative movement disorders regain independence and control in their lives.
Heather Fairhead
Founder & CEO of Phico Therapeutics
Dr Fairhead has over 17 years’ experience directing research teams in a variety of disciplines and has led Phico in developing SASPject technology from a concept through a Phase I clinical trial. Prior to her scientific career, Heather worked for 10 years in sales and marketing in a wide range of industries.
Follow Heather Fairhead:
About Phico Therapeutics: Phico Therapeutics is a developer of novel platform technology designed to overcome antibacterial resistance.
Jonathan Jackson
Co-Founder & CEO of Dimagi
Jonathan Jackson is the CEO and cofounder of Dimagi, a socially conscious technology company that develops CommCare, an open source, scalable mobile platform for low-resource settings. Jonathan is a social entrepreneur and innovator with extensive mobile technology expertise in both low-income and high-income settings. He has co-founded multiple organizations focused on improved healthcare delivery and poverty alleviation globally. As co-founder and CEO of Dimagi, Jonathan has overseen the growth of the company from the founding team to over 100 world-wide employees that operate programs in over 50 countries. He made an uncompromising commitment to open source software and developed a highly interactive, collaborative culture that fosters partnerships across academics, philanthropists, and implementers. Jonathan earned his bachelors and masters degrees in Electrical Engineering and Computer Science from MIT.
Follow Jonathan Jackson:
About Dimagi: Dimagi is an award-winning technology company, developing scalable ICT solutions for low-resource settings.
Benedetto Jacopo Buratti
CEO of Bloomia
Follow Benedetto Jacopo Buratti:
About Bloomia, Einblick: Bloomia is a new medical device that automatically compose the doses and allows you to follow the medical care of your loved ones.
Romain Marmot
Deputy CEO, Chief Operating Officer – US, Oncology Division Coordinator, Co-founder of Voluntis
Romain is Chief Operations Officer of Voluntis and heads the company’s North American operations in Cambridge, MA. He has more than 15 years of experience in digital health and software medical devices. He holds an MSc from École Centrale Paris in applied mathematics.
Follow Romain Marmot:
About Voluntis: Voluntis is a healthcare-related software company specialized in patient relationship management.
Pierre Leurent
Founder & CEO of Voluntis
Pierre has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco. In addition, Pierre is the Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Pierre is a graduate of the Ecole Centrale Paris engineering school.
Follow Pierre Leurent:
About Voluntis: Voluntis is a healthcare-related software company specialized in patient relationship management.
Mick McLean
CEO of Atelerix
Mick is a chemist by training, a biologist by inclination and a businessman by experience, and is CEO for Atelerix. He’s led new ventures and start-up companies in drug discovery and development, pharmaceutical manufacturing, research tools and contract research, and is driven by commercialising great science and growing businesses. He’s easily enthralled by fervent winemakers and plans to own his own vineyard one day…
Follow Mick McLean:
About Atelerix, Atelerix: Atelerix provides storage and transportation of human cells at room temperature to companies.
Adam Keeney
President & CEO of NodThera
Follow Adam Keeney:
About NodThera: NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases.
Robert Ang
President and CEO of Vor Biopharma
Robert Ang is the president and CEO at Vor Biopharma.
Follow Robert Ang:
About Vor Biopharma: Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Hampus Hillerstrom
President and Chief Executive Officer of LuMind IDSC
Hampus Hillerstrom is the President and Chief Executive Officer of LuMind IDSC Foundation and he holds a Master’s in Economics and Finance from the University of St. Gallen, an MBA from Harvard Business School, and an MSc in Health Sciences and Technology from MIT/Harvard Medical School (HST).
Follow Hampus Hillerstrom:
About LuMind IDSC: LuMind IDSC is a nonprofit organization that focuses on down syndrome research, develop gene therapies and empower families with education.
Vitor Pamplona
CEO of EyeNetra
I am mostly known for starting a smart, connected wave of technologies in eye care. We created the first smartphone add-on to measure the refractive error of the eyes, the first at-home vision test to be self-administered by the patient alone, the first to use virtual reality to improve the experience, the first tele-optometry deployment, the first to allow patients to track their own eyesight over time, and the first to complete an integrated solution to remote refractive care worldwide. All of them are marketed products these days (EyeNetra, EyeQue, OnSight, Blink). My research also established the concept and first prototype of a 3D display that eliminates the need for corrective eyewear altogether (Tailored Displays). I operate in the triple frontier between optics, computer science, and vision science from early research to post-breakeven. We have created and deployed refractive innovations that enable eyecare providers to fulfill a vision correction to the ~4.5B people in need. That vision correction is delivered in various form factors: eyeglasses, contacts, Lasik surgery, self-correcting displays, holograms, virtual and augmented reality add-ons, etc; and through a range of companies and products my technology helped create and deploy over the past years. My executive style is based on transparency, freedom, diversity, and trust. Besides the technical knowledge, I have hands-on experience in corporate governance, marketing, sales, fundraising and finances, business development, and intellectual property, both in an NGO and Startup settings. In the side, I co-founded PUB-Boston and the SciBr Foundation to help catalyze Brazilian innovation worldwide. In the past, I co-founded one of the biggest Java User Groups in Brazil (JavaFree), the first Portuguese-speaking on-line portal for Ruby (RubyOnBr), the first 3D game engine for feature phones (M3GE), deployed 11 other open source projects while working full time as a software developer and architect.
Follow Vitor Pamplona:
About EyeNetra, Path Check, SciBr Foundation: EyeNetra is a developer of an eye diagnostics platform used to measure the correction of users’ vision through smartphone-based technology.
Jennifer Barnett
CEO of Monument Therapeutics
Follow Jennifer Barnett:
About Cambridge Cognition, Monument Therapeutics: Monument Therapeutics develops products to treat serious diseases of the central nervous system.
Zied Etleb
Co Founder & Chief Executive Officer of Curiato Inc.
Zied Etleb is the co-founder and chief executive officer at Curiato.
Follow Zied Etleb:
About Curiato Inc.: Provides caregivers and patients a holistic, end-to-end, management system.
James Gibbons
Co-Founder & CEO of SBR Health
James F. Gibbons is a Co-Founder and Chairman of the Board of Directors at SBR Health since 2010. Jim joined the Stanford faculty in 1957, was appointed Professor of Electrical Engineering in 1964, and dean of the School of Engineering in 1984. In 1983 Jim was named Reid Weaver Dennis Professor of Electrical Engineering and in 1984 the Frederick Emmons Terman Dean of the School of Engineering. Jim served as Dean from September 1984 to June 1996. Jim has been an advisor and board member of public companies Cisco Systems, El Paso Energy, Lockheed Martin, Raychem. Jim’s research accomplishments are in the area of semiconductor device analysis, process physics technology and solar energy. Jim has written or co-written several books and nearly 300 papers. Gibbons was named Special Counsel to Stanford University President and Provost for Industry Relations in 1966. Jim is credited with developing the Tutored Video Instruction Technique, a model for education of engineers, with colleagues from Stanford in 1972. In recent years, Jim applied that model to improve productivity and quality in children’s education, particularly for children of migrant farm workers and at-risk teens. Jim has received many awards and was elected a member of the National Academy of Engineering, the National Academy of Sciences and the American Academy or Arts and Sciences. In 1997, Jim was inducted into the Santa Clara County Business Hall of Fame and was one of three chosen for the Silicon Valley Engineering Hall of Fame. Jim received a B.S. (1953) degree from Northwestern University and a Ph.D. (1956) from Stanford University.
Follow James Gibbons:
About SBR Health, Stanford University: SBR Health creates personalized, real-time video communications solutions specialized for the healthcare industry.
Christopher Herot
CEO & Co-Founder of SBR Health
Chris Herot is the CEO and co-founder of SBR Health. Prior to launching SBR in 2010, Chris was Chief Product Officer at VSee Lab, a provider of high quality, low bandwidth and low cost videoconferencing solutions to enterprises and governments. Chris has been a successful business and technology leader in several high growth companies, and directed the advanced technology group for several years at Lotus Development (now IBM) where he was responsible for video, mobile and real-time communications solutions. Chris received his BS and MS degrees from the Massachusetts Institute of Technology where he was on the faculty of the group that became the MIT Media Laboratory.
Follow Christopher Herot:
About SBR Health: SBR Health creates personalized, real-time video communications solutions specialized for the healthcare industry.
Derek Adam Haas
CEO of Avant-garde Health
Follow Derek Adam Haas:
About Avant-garde Health: Avant-garde Health enables hospitals and physicians to understand and improve their care processes, costs, and outcomes.
Mohammad Al-Ubaydli
Founder & CEO of Patients Know Best
Mohammad is founder and CEO of Patients Know Best and has over 15 years of experience in medical software. He trained as a physician at the University of Cambridge; worked as a staff scientist at the National Institutes of Health; and was a management consultant to US hospitals at The Advisory Board Company. He is the author of seven books, including Personal health records: A guide for clinicians and Streamlining Hospital-Patient Communication: Developing High Impact Patient Portals. He is also an honourary senior research associate at UCL medical school for his research on patient-controlled medical records. In 2012 he was elected an Ashoka Fellow as a social entrepreneur for the contributions he has made to patient care.
Follow Mohammad Al-Ubaydli:
About Patients Know Best: Patients Know Best provide hospitals with personal health records software so that their patients can better manage their health.
Andrew Reynolds
CEO of Roadtohealth Group Ltd
Follow Andrew Reynolds:
About Roadtohealth Group Ltd: We’re Road to Health group & we lead a group of strategic partner organisations with shared mission to help people live healthier, happier.
Rod Richards
Founder, CEO of VHSquared
Follow Rod Richards:
About VHSquared: VHsquared is dedicated to the development of novel antibody domains engineered to be stable in the GI tract.
Antony Rix
CEO of Granta Innovation
An entrepreneur with an engineering background, Antony has spent over 20 years working in telecommunications, wireless technology, medical devices and product development. He started his career at a major telecoms research laboratory, then co-founded Psytechnics, a spin-out commercialising network quality assessment and monitoring technology. He then spent more than a decade at TTP, the leading technology and product development consultancy, before joining 8power as co-founder and CEO. He is currently founder and CEO at Lucida Medical, developing AI for cancer screening using MRI.
Follow Antony Rix:
About Lucida Medical: Research, consulting and development of AI and ML applications in business and healthcare
Huw Jones
Chief Executive Officer & Executive Chairman of Chronos Therapeutics
Follow Huw Jones:
About Chronos Therapeutics, Evgen Pharma: Chronos Therapeutics is a drug development company focused on the development of drugs for the treatment of age-related diseases.
Gleb Kuznetsov
Co-Founder and CEO of Manifold Bio
Gleb Kuznetsov is the Co-Founder and CEO at Manifold Bio.
Follow Gleb Kuznetsov:
About Manifold Bio: Manifold Bio is building a protein barcoding platform to bring the power of multiplexed measurement.
David Mountford
CEO of British Equine Veterinary Association
David Mountford is Co-Founder & COO at MedCell Bioscience.
Follow David Mountford:
About British Equine Veterinary Association: British Equine Veterinary Association is a world leading equine veterinary association with members across the globe.
Danielle Zurovcik
Founder & CEO of WiCare
Danielle Zurovcik is the founder and CEO of WiCare.
Follow Danielle Zurovcik:
About WiCare: WiCare develops innovative medical devices that are clinically effective and affordable worldwide.
Paul Pyzowski
CEO of Altimate Health
Paul Pyzowski is the Chief Executive Officer at Altimate Health.
Follow Paul Pyzowski:
About Altimate Health: Altimate Health is a Digitally-Enabled Specialty Healthcare Company for Serious Mental Illness
Lucy Jung
Founder & Chief Executive Officer of Charco Neurotech
Lucy Jung is the Founder and Chief Executive Officer at Charco Neurotech.
Follow Lucy Jung:
About Charco Neurotech: Charco Neurotech is a medical technology company that develops non-invasive wearable devices.
Goutam Reddy
Founder, CEO of Abiogenix
‘Greddy’ devised the overall architecture of the uBox system, including designing the electronics and firmware of the uBox and uKey. Greddy holds past EE design experience from working for MolySym as well as sensing and robotics from the Biomechatronics Group at the MIT Media Lab. He also has relevant developing-world experience from Developing World Prosthetics, a non-profit he co-founded to improve low-cost rehabilitation devices. Greddy received a Master’s in Electrical Engineering and Computer Science (EECS), as well as B.S. degrees in Mathematics and EECS from MIT.
Follow Goutam Reddy:
About Abiogenix: Abiogenix helps patients improve their medication adherence, which in turn reduces healthcare costs for providers and payers and increases
Michael Segal
CEO of wHealthy Solutions
Follow Michael Segal:
About wHealthy Solutions: wHealthy provides its users with diet-agnostic solutions that allow them to select their own diet type.
Nell Meosky Luo
Founder & CEO of Folia Health
Nell Meosky Luo is a Founder and CEO at Folia Health, Inc.
Follow Nell Meosky Luo:
About Folia Health: Folia Health is a povider of an easy-to-use tool intended to help pediatric chronic disease patients and their families.
Jung Taek Oh
CEO of UrCare
Jung-Taek Oh is CEO of urCare, a chronic care management service company specialized on bridging non-medical and medical service. We provide better Health outcomes, reduce healthcare cost and make every life meaningful.
Follow Jung Taek Oh:
About UrCare: UrCare connects caregiver agencies to healthcare providers.
David S. Barlow
CEO of Molecular Insight Pharmaceuticals
David S. Barlow is CEO of Molecular InsightPharmaceuticals Inc.
Follow David S. Barlow:
About : Molecular Insight Pharmaceuticals is a biopharmaceutical company specializing in the emerging field of molecular medicine.
Joanna Burnett
Co-founder and CEO of GPrX Data
Follow Joanna Burnett:
About GPrX Data: GPrX Data translates NHS practice level prescribing data into easily-reviewed intelligence.
Jim Huntington
CEO of ApcinteX
Jim Huntington joined APCINTEX as CEO in 2018.
Follow Jim Huntington:
About ApcinteX, University of Cambridge: ApcinteX develops and markets anticoagulant APC pathway to treat haemophilia.
Pedro De Abreu
CEO of 14x Innovation Group
Pedro De Abreu is the founder of 14x Innovation Group, an innovation development practice that specializes in building innovation capabilities in individuals and organizations in business, government, and education by helping individuals leverage the impact of the brain and behavior on individual performance and by providing organizations with a framework for organizational innovation and change. 14x Innovation Group runs intensive workshops, provides consulting sessions, and keynote speeches. Through 14x, Pedro has traveled to countries including Dubai, Oman, Brazil, Kuwait, and the Kingdom of Bahrain to help organizations and individuals innovate. Pedro has a master’s degree in Applied Psychology, Neuroscience, and Practice in Mind, Brain, and Education from Harvard University. At Harvard, Pedro conducted research on the interplay of dispositions and environmental factors in the development of high performing individuals as well as on organizational behavior. Pedro assists with research in future self-perception and affective forecasting at Edgar Pierce Professor of Psychology Daniel Gilbert’s laboratory at Harvard University.
Follow Pedro De Abreu:
About 14X IG (14X Innovation Group), 14x Innovation Group: 14x Innovation Group helps organizations and individuals leverage the impact of the brain on individual performance.
Thomas Goijarts
Founder & CEO of Caro Health
Follow Thomas Goijarts:
About Caro Health: Caro Health delivers a digital companion that provides relevant content, guidance and actionable notification to improve patient outcomes.
